Serum concentration of visfatin is decreased in patients with chronic heart failure

• Autorzy: Straburzynska-Migaj E. , Pilaczynska-Szczesniak L. , Nowak A. , Straburzynska-Lupa A. , Sliwicka E. , Grajek S.
• Języki publikacji: EN

Abstrakty

EN

 Background. There is an increasing interest in the role of adipocytokines in cardiovascular pathophysiology. Aim. The aim of the study was to compare visfatin levels, a novel adipokine, in patients with heart failure (HF) due to the left ventricular systolic dysfunction with those in age- and body mass index (BMI) - matched healthy controls in relation to the parameters of glucose metabolism and high sensitivity C-reactive protein (hsCRP) levels. Material/Subjects and Methods. The study population consisted of 28 males with systolic HF referred for cardiopulmonary exercise testing, divided into two subgroups based on their NYHA class (HF patients NYHAI+II, n=17, and HF patients NYHAIII+IV, n=11), and 23 controls. The following indices were measured in a serum samples: visfatin, hsCRP, glucose and lipid metabolism parameters, and the insulin resistance index HOMAIR (homeostasis model assessment insulin resistance) was calculated. Results. Concentrations of visfatin and high-density lipoprotein cholesterol (HDL-cholesterol) in the HF subjects were significantly lower (p ≤ 0.01) than in controls. The Kruskal-Wallis test showed significant differences between three groups (controls and both subgroups of heart failure patients) in mean levels of visfatin, hsCRP, glucose, HOMAIR and HDL-cholesterol. Conclusion. Serum visfatin concentrations in patients with systolic HF, particularly with more advanced NYHA classes, are significantly lower in comparison to healthy controls and are independent of age or anthropometric and metabolic parameters.

Słowa kluczowe

EN

serum concentration; visfatin; patient; chronic heart failure; insulin resistance; C-reactive protein; lipoprotein; heart failure; cardiovascular disease; pathophysiology

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2012
• Tom: 59
• Numer: 3
• Opis fizyczny: p.339=343,fig.,ref.

Twórcy

autor

Straburzynska-Migaj E.

• Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland

autor

Pilaczynska-Szczesniak L.

autor

Nowak A.

autor

Straburzynska-Lupa A.

autor

Sliwicka E.

autor

Grajek S.

Bibliografia

• Alghasham AA, Barakat YA (2008) Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy. Saudi Med J 29: 185-192. 
• Caixàs A, Tirado R, Vendrell J, Gallart L, Megía A, Simón I, Llauradó G, González-Clemente JM, Giménez-Palop O (2009) Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol (Oxf) 71: 733-738. 
• Chan TF, Chen YL, Lee CH, Chou FH, Wu LC, Jong SB, Tsai EM (2006) Decreased plasma visfatin concentration in women with gestational diabetes mellitus. J Soc Gynecol Investig 13: 364-367. 
• Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91: 295-299. 
• Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA (2006) Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 8: 355-360. 
• Clark AL, Poole-Wilson PA, Coats AJ (1996) Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol 28: 1092-1102. 
• Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P, Halvorsen B (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis. Possible role in inflammation and plaque destabilization. Circulation 115: 972-980. 
• de Luis DA, Sagrado MG, Conde R, Aller R, Izaola O (2009) Relation of visfatin to cardiovascular risk factors and adipocytokines in patients with impaired glucose tolerance. Nutrition doi:10.1016/j.nut.2008.11.005. 
• Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJ, Anker SD (2005) Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46: 1019-1026. 
• Ersoy C, Sadikoglu G, Orhan H, Guclu M, Sarandol E, Akgun MD, Ozcakir A, Imamoglu S (2010) Body fat distribution has no effect on serum visfatin levels in healthy female subjects. Cytokine 49: 275-278. 
• Esteghamati A, Alamdari A, Zandieh A, Elahi S, Khalilzadeh O, Nakhjavani M, Meysamie A (2011) Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract 91: 154-158. 
• Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502. 
• Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I (2005) Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430. 
• Hausenloy DJ (2009) Drug discovery possibilities from visfatin cardioprotection? Curr Opin Pharmacol 9: 202-207. 
• Ho YL, Lin YH, Lee CM, Hsu RB, Ting HT, Chou NK, Chao CL, Wang SS, Hsu HC, Chen MF (2009) Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide. Clin Biochem 42: 1407-1412. 
• Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, Shang W, Li F, Ma Q, Yang Y, Chen M (2008) Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 79: 412-418. 
• Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, Lampropoulos S (2011) Serum levels of vaspin and visfatin in patients with coronary artery disease - Kozani study. Clin Chim Acta 412: 48-52. 
• Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, Bienkiewicz M, Vatish M, Lewinski A, Prelevic GM, Randeva HS (2007) Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 50: 1033-1037. 
• Liu SW, Qiao SB, Yuan JS, Liu DQ (2009) Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 71: 202-207. 
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28: 412-419. 
• Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178: 1748-1758. 
• Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91: 3165-3170. 
• Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ, Anker SD (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102: 3060-3067. 
• Smith J, Al-Amri M, Sniderman A, Cianflone K (2006) Visfatin concentration in Asian Indians is correlated with high density lipoprotein cholesterol and apolipoprotein A1. Clin Endocrinol (Oxf) 65: 667-672. 
• Straburzyńska-Lupa A, Nowak A, Pilaczyńska-Szcześniak Ł, Straburzyńska-Migaj E, Romanowski W, Karolkiewicz J, Sliwicka E (2010) Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis. Clin Exp Rheumatol 28: 19-24. 
• Straburzyńska-Migaj E, Leśniewska K, Ochotny R, Straburyńska-Lupa A, Baszko A, Wiktorowicz K, Cieśliński A (2004) Cardiopulmonary exercise testing and cytokines in chronic heart failure. Comparison of patients with ischaemic and with dilated cardiomyopathy. Pol Arch Med Wewn 111: 693-701. 
• Straburzyńska-Migaj E, Ochotny R, Cieśliński A (2007) Impaired glucose tolerance worsens exercise capacity and ventilatory response to exercise in patients with chronic heart failure. Kardiol Pol 65: 354-360. 
• Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue their relation to the metabolic syndrome. Endocr Rev 21: 697-738. 
• Wang P, van Greevenbroek MM, Bouwman FG, Brouwers MC, van der Kallen CJ, Smit E, Keijer J, Mariman EC (2007) The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 454: 971-976. 
• Wolk R, Somers VK (2006) Leptin and vascular function: friend or foe? Eur Heart J 27: 2263-2265. 
• Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocełak P, Semik-Grabarczyk E, Holecki M, Dabrowski P, Skorupa A (2007) Serum concentration of visfatin in obese women. Metabolism 56: 1131-1134.